Patents Examined by Changhwa J. Cheu
  • Predicting mortality and detecting severe disease
    Patent number: 11016103
    Abstract: Measurement of circulating ST2 and/or IL-33 concentrations is useful for the prognostic evaluation of subjects, in particular for the prediction of adverse clinical outcomes, e.g., mortality, and the detection of severe disease.
    Type: Grant
    Filed: August 13, 2018
    Date of Patent: May 25, 2021
    Assignee: Critical Care Diagnostics, Inc.
    Inventors: James V. Snider, Sven Jacobson
  • Method for diagnosing or monitoring kidney function or diagnosing kidney dysfunction
    Patent number: 11016107
    Abstract: A method for (a) diagnosing or monitoring kidney function in subject or (b) diagnosing kidney dysfunction in a subject or (c) predicting or monitoring the risk of an adverse events in a diseased subject or (d) predicting or monitoring the success of a therapy or intervention comprising determining the level of Pro-Enkephalin (PENK) or fragments thereof of at least 5 amino acids in a bodily fluid obtained from said subject; and correlating said level of Pro-Enkephalin or fragments thereof with (a) kidney function in a subject or (b) kidney dysfunction in said subject or (c) enhanced risk of adverse events or (d) success of a therapy or intervention in a diseased subject.
    Type: Grant
    Filed: October 29, 2018
    Date of Patent: May 25, 2021
    Assignee: SPHINGOTEC GMBH
    Inventor: Andreas Bergmann
  • In vitro method for identifying a pregnancy related disease
    Patent number: 11009512
    Abstract: The present invention is focused on an in vitro method for identifying or screening human subjects at risk of suffering from a pregnancy related disease, in particular from gestational diabetes mellitus or preeclampsia, departing from the level of expression or concentration of a series of biomarkers isolated from a minimally-invasive sample such as gingival crevicular fluid (GCF). Moreover, the method of the invention offers high sensitivity and specificity at an early stage of the pregnancy (see the Examples and figures shown below), which means that it is a strong and cost-effective method for the detection of a pregnancy related disease, in particular gestational diabetes mellitus or preeclampsia, at an early stage of the disease thus procuring effective treatment, avoiding significant long-term adverse effects for both mother and baby.
    Type: Grant
    Filed: September 12, 2016
    Date of Patent: May 18, 2021
    Assignee: UNIVERSIDAD DE LOS ANDES
    Inventors: Alejandra Chaparro Padilla, Sebastian Illanes Lopez
  • Trimethylamine-containing compounds for diagnosis and prediction of disease
    Patent number: 10983100
    Abstract: The present invention provides markers and methods for determining whether a subject, particularly a human subject, has or is at risk of developing, a disease such as cardiovascular disease, diabetes mellitus, insulin resistance, metabolic syndrome, NAFLD (Nonalcoholic Fatty Liver Disease) or NASH (Nonalcoholic Steatohepatitis) (e.g., within the ensuing year, two years, and/or three years). The present application also relates to the use of such markers and methods for monitoring the status of such diseases in a subject or the effects of therapeutic agents on subjects with such diseases.
    Type: Grant
    Filed: February 1, 2019
    Date of Patent: April 20, 2021
    Assignee: The Cleveland Clinic Foundation
    Inventors: Stanley L. Hazen, Zeneng Wang, Bruce S. Levison
  • Diagnostic and prognostic methods for cardiovascular diseases and events
    Patent number: 10983135
    Abstract: Compositions and methods are provided for diagnosis and/or prognosis of cardiovascular diseases or events in a subject. In some embodiments, the method includes measuring and comparing the level of particular proteins to other proteins. In other embodiments, the method includes comparison with clinical variable information.
    Type: Grant
    Filed: February 1, 2017
    Date of Patent: April 20, 2021
    Assignee: PREVENCIO, INC.
    Inventors: Rhonda Fay Rhyne, Craig Agamemnon Magaret, John Edward Strobeck, James Louis Januzzi, Jr.
  • System, device and method for high-throughput multi-plexed detection
    Patent number: 10983116
    Abstract: The present invention relates to a system, device, and method for the high throughput multiplexed detection of a wide number of compounds. The invention comprises of a microwell array coupled to a capture agent array to form a plurality of interfaces between a microwell and a set of immobilized capture agents. The set of capture agents comprises a plurality of distinguishable features, with each feature corresponding to the detection of a particular compound of interest. In certain embodiments, each microwell is configured to contain a single cell. The invention is therefore capable of performing a high throughput analysis of single cell profiles, including profiles of secreted compounds.
    Type: Grant
    Filed: March 6, 2019
    Date of Patent: April 20, 2021
    Assignee: Yale University
    Inventors: Rong Fan, Yao Lu, Jonathan Chen
  • Ligand identification by co-fractionation
    Patent number: 10976310
    Abstract: This invention relates to a method of determining ligands of macromolecules, said method comprising or consisting of (a) subjecting a sample comprising (i) complexes formed by said macromolecules and said ligands and (ii) unbound ligands to a method which separates said complexes from said unbound ligands; (b) releasing ligands from complexes obtained in step (a); and (c) subjecting the released ligands obtained in step (b) to a chemical analysis method, thereby determining said ligands of said macromolecules.
    Type: Grant
    Filed: May 29, 2017
    Date of Patent: April 13, 2021
    Inventors: Aleksandra Skirycz, Sylwia Kierszniowska, Daniel Veyel, Lothar Willmitzer, Monika Chodasiewicz
  • Multi-stage, multiplexed target isolation and processing from heterogeneous populations
    Patent number: 10962527
    Abstract: A system and method for isolating target substrates includes a microfluidic chip, comprising a plurality of processing units, each processing unit comprising: an inlet port, a plurality of first chambers connected to the inlet port by a fluid channel, the fluid channel comprising a plurality of valves, a plurality of second chambers, each of the second chambers connected to a respective first chamber by a fluid channel, each fluid channel including a controllable blocking valve, and a plurality of respective outlet ports, each outlet port in fluid communication with a respective one of said second chambers and each outlet port including a blocking valve. A magnet is adjacent the microfluidic chip and is movable relative to the microfluidic chip. A valve control is capable of actuating certain ones of the controllable blocking valves in response to a control signal.
    Type: Grant
    Filed: February 3, 2017
    Date of Patent: March 30, 2021
    Assignees: THE BROAD INSTITUTE, INC., MASSACHUSETTS INSTITUTE OF TECHNOLOGY, THE GENERAL HOSPITALL CORPORATION
    Inventors: Paul Blainey, Dwayne Vickers, Nir Hacohen
  • Biomarkers and methods for assessing myocardial infarction and serious infection risk in rheumatoid arthritis patients
    Patent number: 10962552
    Abstract: Provided herein are methods for assessing risk of infection or cardiovascular disease (CVD) in a subject with an inflammatory disease, e.g., rheumatoid arthritis. The methods include performing immunoassays to generate scores based on quantitative data for expression of biomarkers relating to inflammatory biomarkers with or without additional clinical variables to assess infection and CVD risk. Also provided are uses of inflammatory biomarkers for guiding treatment decisions.
    Type: Grant
    Filed: March 10, 2020
    Date of Patent: March 30, 2021
    Assignees: CRESCENDO BIOSCIENCE, INC., UAB RESEARCH FOUNDATION
    Inventors: Kerri Ford, Jeffrey R. Curtis
  • Lipidomic biomarkers for identification of high-risk coronary artery disease patients
    Patent number: 10955427
    Abstract: The present invention inter alia provides a method, and use thereof, of predicting severe CVD complications such as AMI or CVD death by detecting the lipid concentrations or lipid ratios of a biological sample and comparing it to a control and has identified specific lipid markers that are more specific and sensitive in predicting these CVD complications than currently utilized clinical markers. Also provided is an antibodies towards said lipids, and the use thereof for predicting, diagnosing, preventing and/or treating CVD complications. The invention additionally relates to kits comprising lipids and/or an antibody thereto, for use in the prediction and/or diagnosis of CVD complications.
    Type: Grant
    Filed: March 4, 2019
    Date of Patent: March 23, 2021
    Assignee: ZORA BIOSCIENCES OY
    Inventors: Reijo Laaksonen, Kim Ekroos, Reini Hurme, Riikka Katainen
  • Methods of assaying proteins
    Patent number: 10948488
    Abstract: Methods and systems for identifying a protein within a sample are provided herein. A panel of antibodies are acquired, none of which are specific for a single protein or family of proteins. Additionally, the binding properties of the antibodies in the panel are determined. Further, the protein is iteratively exposed to a panel of antibodies. Additionally, a set of antibodies which bind the protein are determined. The identity of the protein is determined using one or more deconvolution methods based on the known binding properties of the antibodies to match the set of antibodies to a sequence of a protein.
    Type: Grant
    Filed: October 21, 2019
    Date of Patent: March 16, 2021
    Assignee: Nautilus Biotechnology, Inc.
    Inventor: Parag Mallick
  • Calcium binding protein, spermatid specific 1, as a biomarker for diagnosis or treatment of stress
    Patent number: 10942174
    Abstract: A method of determining risk of stress in a subject involves determining in a biological sample, the level of one or more forms of calcium binding protein spermatid specific 1 protein, wherein the one or more forms comprise one or more of 12 kDa, 15 kDa, 18 kDa, 20 kDa, 27 kDa, 33 kDa, 55 kDa, or 90 kDa forms; comparing the level of the one or more forms in the sample with the level of the one or more forms in a normal control; determining whether the subject has risk of stress in accordance with the result; wherein a difference in the level of the one or more forms relative to the level of the normal control, is indicative of stress or responsiveness to stressful stimuli; and treating the subject with a stress management program that involves using one or more forms of 12 kDa, 15 kDa, 18 kDa, 20 kDa, 27 kDa, 33 kDa, 55 kDa, or 90 kDa forms as therapeutic targets.
    Type: Grant
    Filed: March 14, 2017
    Date of Patent: March 9, 2021
    Inventors: Dean Befus, Thomas Ritz, Chris St. Laurent, Katherine St. Laurent
  • Assay with increased dynamic range
    Patent number: 10942179
    Abstract: Provided herein are assays and kits useful for avoiding “prozone phenomenon” or “hook effect” and which expand the range of accurately measurable analyte concentrations.
    Type: Grant
    Filed: August 8, 2018
    Date of Patent: March 9, 2021
    Assignee: Abbott Laboratories
    Inventors: Barry L. Dowell, Susan Gayda, Qiaoqiao Ruan, Joseph P. Skinner, Sergey Y. Tetin
  • Compositions and methods for detecting and/or treating inflammation
    Patent number: 10935556
    Abstract: The present disclosure relates to assays and methods for the detection of renal inflammation by measuring the level of P2Y14 and/or UDP-glucose in a sample from a subject, such as a urine sample. The present disclosure also relates to methods for the treatment of renal inflammation by administering a P2Y14 inhibitor.
    Type: Grant
    Filed: April 4, 2019
    Date of Patent: March 2, 2021
    Assignee: THE GENERAL HOSPITAL CORPORATION
    Inventors: Sylvie Breton, Dennis Brown, Anie Azroyan, Virna F. Cortez-Retamozo, Mikael Pittet
  • Methods of assaying proteins
    Patent number: 10921317
    Abstract: Methods and systems for identifying a protein within a sample are provided herein. A panel of antibodies are acquired, none of which are specific for a single protein or family of proteins. Additionally, the binding properties of the antibodies in the panel are determined. Further, the protein is iteratively exposed to a panel of antibodies. Additionally, a set of antibodies which bind the protein are determined. The identity of the protein is determined using one or more deconvolution methods based on the known binding properties of the antibodies to match the set of antibodies to a sequence of a protein.
    Type: Grant
    Filed: February 12, 2020
    Date of Patent: February 16, 2021
    Assignee: Nautilus Biotechnology, Inc.
    Inventor: Parag Mallick
  • Assay for the diagnosis of peanut allergy
    Patent number: 10871493
    Abstract: A diagnostically useful carrier has a polypeptide for specifically capturing an antibody to Ara h 7 isotype 7.0201 in a sample from a subject. A method includes detecting in a sample from a subject the presence or absence of an antibody to Ara h 7 isotype 7.0201. A pharmaceutical composition includes Ara h 7 isotype 7.0201 or a variant thereof.
    Type: Grant
    Filed: February 15, 2018
    Date of Patent: December 22, 2020
    Assignee: EUROIMMUN Medizinische Labordiagnostika AG
    Inventors: Waltraud Suer, Stefanie Rohwer, Bettina Brix, Alf Weimann
  • Method for making a temperature-independent paper test strip for detecting zika virus
    Patent number: 10866243
    Abstract: A method for making and a resultant paper test strip product for detecting Zika antibodies indicating the presence of Zika virus in a patient sample. The paper test strip includes a strip of filter paper; and a silk fibroin solution applied to the strip of filter paper wherein the silk fibroin solution is mixed with an enzyme solution in phosphate buffered saline buffer.
    Type: Grant
    Filed: August 14, 2018
    Date of Patent: December 15, 2020
    Inventor: Ashlynn Gallagher
  • Competition assay
    Patent number: 10845362
    Abstract: The application provides competition assays used to detect free-light chains or intact immunoglobulins comprising incubating the sample with anti-FLC antibody, or heavy chain class-light chain type-specific antibodies, or fragments of such antibodies, and a known amount of FLC or intact immunoglobulin and detecting the binding of the antibody to the known amount of FLC or immunoglobulin. Assay kits and methods of producing particles coated with FLC are also provided.
    Type: Grant
    Filed: July 19, 2011
    Date of Patent: November 24, 2020
    Assignee: THE BINDING SITE GROUP LIMITED
    Inventors: Graham Peter Mead, Hugh Carr Smith, Arthur Randall Bradwell
  • Cell-specific signaling biomarker analysis by high parameter cytometry; sample processing, assay set-up, method, analysis
    Patent number: 10845363
    Abstract: The present invention recognizes that current clinical laboratory testing methods for multiparametric single cell analysis are limited to analysis of intact live cells, and are insufficient for identification of signaling activation profile defining certain cell types, including but not limited to neoplastic and immunologically activated cell subsets. One aspect of the present invention generally relates to marker selection in panels to include proteins routinely assessed in standard FCM, while preferably also incorporating markers for surface receptor proteins within activated signaling cascades.
    Type: Grant
    Filed: May 2, 2018
    Date of Patent: November 24, 2020
    Assignee: DeePath Medical Diagnostics, Inc.
    Inventor: Jita De
  • Quantitative massively parallel proteomics
    Patent number: 10809266
    Abstract: Provided herein are compositions and methods for the identification of an expression profile in a single cell or population of cells. Kits for use with the disclosed methods are also provided, including antibodies, with a unique molecular identifier and antibody identifier, and primers for amplification of the antibody identifier sequence.
    Type: Grant
    Filed: July 21, 2017
    Date of Patent: October 20, 2020
    Assignee: VERILY LIFE SCIENCES LLC
    Inventors: Ian Peikon, Gary Tong, Daniel Liu, Ci Chu